Quick Answer
REGENXBIO Inc. reported Cash and Equivalents of $34.47 million for fiscal year 2025.
REGENXBIO Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $34.47M | -40.1% |
| 2024 | $57.53M | +66.6% |
| 2023 | $34.52M | -64.4% |
| 2022 | $96.95M | -71.9% |
| 2021 | $345.21M | +2.0% |
| 2020 | $338.43M | +386.8% |
| 2019 | $69.51M | -8.0% |
| 2018 | $75.56M | +62.0% |
| 2017 | $46.66M | +87.8% |
| 2016 | $24.84M | -54.1% |
| 2015 | $54.12M | +4727.5% |
| 2014 | $1.12M | +0.2% |
| 2013 | $1.12M | -48.3% |
| 2012 | $2.17M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $58.80M | +3.9% | -26.1% |
| June 30, 2025 | $79.56M | +37.7% | -38.9% |
| March 31, 2025 | $130.10M | +15.2% | +126.2% |
| December 31, 2024 | $57.53M | +66.6% | +1.6% |
| September 30, 2024 | $56.62M | +6.7% | -2.0% |
| June 30, 2024 | $57.77M | -15.8% | -48.9% |
| March 31, 2024 | $112.97M | +61.2% | +227.3% |
| December 31, 2023 | $34.52M | -64.4% | -34.9% |
- REGENXBIO Inc. showed a decrease of -40.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2012–2025 period, REGENXBIO Inc.’s cash and equivalents has grown by 1491.2% (from $2.17 million to $34.47 million).
- The most recent figure is from REGENXBIO Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: